Dreyling, A. “Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas”. Hematology Meeting Reports (formerly Haematologica Reports) 2, no. 5 (June 23, 2009). Accessed July 22, 2024. https://www.pagepress.org/journals/hmr/article/view/749.